case_images: PMC11782362_01
case_images: Clinical course of the patient with second relapsed DS-ALL. BLIN, blinatumomab; BZM, bortezomib; InO, inotuzumab ozogamycin
case_images: 12185_2024_3890_Fig1_HTML.jpg
case_images: PMC11782362_01_12185_2024_3890_Fig1_HTML.jpg
case_images: Fig1
case_images: After partial cytoreduction with cytarabine (20 mg/m2 daily for 5 days), single-agent blinatumomab was administered for 4 weeks; however, 81% of the lymphoid blasts positive for CD19 were still observed in the BM (Fig. 1). Therefore, bortezomib-combined chemotherapy was initiated as previously reported (Fig. 1).
case_images: Clinical course of the patient from the inotuzumab ozogamicin initiation. Areas with platelet levels below 50 x 109 /L are highlighted by gray shading. Open triangle, inotuzumab ozogamycin 0.8 mg/m2; filled triangle, inotuzumab ozogamycin 0.5 mg/m2; InO, inotuzumab ozogamycin
case_images: 12185_2024_3890_Fig2_HTML.jpg
case_images: PMC11782362_01_12185_2024_3890_Fig2_HTML.jpg
case_images: Fig2
case_images: However, a second dose was administered 4 weeks after the initial InO treatment due to prolonged thrombocytopenia (Fig. 2). Although subsequent InO treatments also needed to be delayed (Fig. 2), the patient has been in CR for the last 20 months following InO initiation, with no toxicity besides prolonged thrombocytopenia.